Fosfomycin

what was old is new again

Minyon L. Avent, Benjamin A. Rogers, Allen C. Cheng, Eugene Athan, Joshua R. Francis, Matthew J. Roberts, David L. Paterson, Patrick N.A. Harris

    Research output: Contribution to journalEditorialResearchpeer-review

    Abstract

    With the rising prevalence of antibiotic resistance in bacteria, there is a need to develop new antibiotics and re‐visit older antibiotics where there are no available alternatives. Fosfomycin, first discovered in the 1960s,1 has a long history of use in some countries (including the United States, Japan and several European countries), particularly for urinary tract infections.2 In Australia, oral fosfomycin trometamol, previously only available through the Special Access Scheme, has recently been approved by the Therapeutic Goods Administration for the management of acute, uncomplicated urinary tract infections in females over 12 years of age, caused by Enterobacteriaceae (including Escherichia coli) and Enterococcus faecalis, where the standard recommended agents are not effective. Currently, it is not subsidised by the Pharmaceutical Benefits Scheme.
    Original languageEnglish
    Pages (from-to)1425-1429
    Number of pages5
    JournalInternal Medicine Journal
    Volume48
    Issue number12
    DOIs
    Publication statusPublished - 5 Dec 2018

    Fingerprint

    Fosfomycin
    Anti-Bacterial Agents
    Tromethamine
    Enterococcus faecalis
    Enterobacteriaceae
    Microbial Drug Resistance
    Urinary Tract
    Urinary Tract Infections
    Japan
    Escherichia coli
    Bacteria
    Pharmaceutical Preparations
    Therapeutics

    Cite this

    Avent, M. L., Rogers, B. A., Cheng, A. C., Athan, E., Francis, J. R., Roberts, M. J., ... Harris, P. N. A. (2018). Fosfomycin: what was old is new again. Internal Medicine Journal, 48(12), 1425-1429. https://doi.org/10.1111/imj.14122
    Avent, Minyon L. ; Rogers, Benjamin A. ; Cheng, Allen C. ; Athan, Eugene ; Francis, Joshua R. ; Roberts, Matthew J. ; Paterson, David L. ; Harris, Patrick N.A. / Fosfomycin : what was old is new again. In: Internal Medicine Journal. 2018 ; Vol. 48, No. 12. pp. 1425-1429.
    @article{68071e7c15d54f9e966b594131006bec,
    title = "Fosfomycin: what was old is new again",
    abstract = "With the rising prevalence of antibiotic resistance in bacteria, there is a need to develop new antibiotics and re‐visit older antibiotics where there are no available alternatives. Fosfomycin, first discovered in the 1960s,1 has a long history of use in some countries (including the United States, Japan and several European countries), particularly for urinary tract infections.2 In Australia, oral fosfomycin trometamol, previously only available through the Special Access Scheme, has recently been approved by the Therapeutic Goods Administration for the management of acute, uncomplicated urinary tract infections in females over 12 years of age, caused by Enterobacteriaceae (including Escherichia coli) and Enterococcus faecalis, where the standard recommended agents are not effective. Currently, it is not subsidised by the Pharmaceutical Benefits Scheme.",
    author = "Avent, {Minyon L.} and Rogers, {Benjamin A.} and Cheng, {Allen C.} and Eugene Athan and Francis, {Joshua R.} and Roberts, {Matthew J.} and Paterson, {David L.} and Harris, {Patrick N.A.}",
    year = "2018",
    month = "12",
    day = "5",
    doi = "10.1111/imj.14122",
    language = "English",
    volume = "48",
    pages = "1425--1429",
    journal = "Internal Medicine Journal",
    issn = "1444-0903",
    publisher = "Wiley-Blackwell",
    number = "12",

    }

    Avent, ML, Rogers, BA, Cheng, AC, Athan, E, Francis, JR, Roberts, MJ, Paterson, DL & Harris, PNA 2018, 'Fosfomycin: what was old is new again', Internal Medicine Journal, vol. 48, no. 12, pp. 1425-1429. https://doi.org/10.1111/imj.14122

    Fosfomycin : what was old is new again. / Avent, Minyon L.; Rogers, Benjamin A.; Cheng, Allen C.; Athan, Eugene; Francis, Joshua R.; Roberts, Matthew J.; Paterson, David L.; Harris, Patrick N.A.

    In: Internal Medicine Journal, Vol. 48, No. 12, 05.12.2018, p. 1425-1429.

    Research output: Contribution to journalEditorialResearchpeer-review

    TY - JOUR

    T1 - Fosfomycin

    T2 - what was old is new again

    AU - Avent, Minyon L.

    AU - Rogers, Benjamin A.

    AU - Cheng, Allen C.

    AU - Athan, Eugene

    AU - Francis, Joshua R.

    AU - Roberts, Matthew J.

    AU - Paterson, David L.

    AU - Harris, Patrick N.A.

    PY - 2018/12/5

    Y1 - 2018/12/5

    N2 - With the rising prevalence of antibiotic resistance in bacteria, there is a need to develop new antibiotics and re‐visit older antibiotics where there are no available alternatives. Fosfomycin, first discovered in the 1960s,1 has a long history of use in some countries (including the United States, Japan and several European countries), particularly for urinary tract infections.2 In Australia, oral fosfomycin trometamol, previously only available through the Special Access Scheme, has recently been approved by the Therapeutic Goods Administration for the management of acute, uncomplicated urinary tract infections in females over 12 years of age, caused by Enterobacteriaceae (including Escherichia coli) and Enterococcus faecalis, where the standard recommended agents are not effective. Currently, it is not subsidised by the Pharmaceutical Benefits Scheme.

    AB - With the rising prevalence of antibiotic resistance in bacteria, there is a need to develop new antibiotics and re‐visit older antibiotics where there are no available alternatives. Fosfomycin, first discovered in the 1960s,1 has a long history of use in some countries (including the United States, Japan and several European countries), particularly for urinary tract infections.2 In Australia, oral fosfomycin trometamol, previously only available through the Special Access Scheme, has recently been approved by the Therapeutic Goods Administration for the management of acute, uncomplicated urinary tract infections in females over 12 years of age, caused by Enterobacteriaceae (including Escherichia coli) and Enterococcus faecalis, where the standard recommended agents are not effective. Currently, it is not subsidised by the Pharmaceutical Benefits Scheme.

    UR - http://www.scopus.com/inward/record.url?scp=85057711656&partnerID=8YFLogxK

    U2 - 10.1111/imj.14122

    DO - 10.1111/imj.14122

    M3 - Editorial

    VL - 48

    SP - 1425

    EP - 1429

    JO - Internal Medicine Journal

    JF - Internal Medicine Journal

    SN - 1444-0903

    IS - 12

    ER -

    Avent ML, Rogers BA, Cheng AC, Athan E, Francis JR, Roberts MJ et al. Fosfomycin: what was old is new again. Internal Medicine Journal. 2018 Dec 5;48(12):1425-1429. https://doi.org/10.1111/imj.14122